Introduction

Axcan Pharma is a leading specialty pharmaceutical company that develops and markets a range of products to treat gastrointestinal diseases and disorders, such as inflammatory bowel disease, cholestatic liver diseases, irritable bowel syndrome, and complications related to pancreatic insufficiency.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Axcan’s strategy is to grow its business by increasing market penetration and sales of existing products, developing and obtaining marketing approval for new products, in-licensing products and acquiring new products or companies, development of its research and development portfolio, and expanding geographically. Currently, the company markets more than 40 products and dosage strengths worldwide in the field of gastroenterology. Axcan’s major products include Ultrase (Pancreatic Diseases), Urso (Cirrhosis), Canasa (Proctitis) and Carafate (Duodenal Ulcer). Axcan’s all of the revenue has historically been and continues to be principally derived from sales of pharmaceutical products. The company’s total revenues increased at a CAGR of 22% during 2002-2006, from $132 million to $292 million.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization .

Report Highlights

[Studien Infos ausblenden]